ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Alpha Healthcare Acquisition Corporation

Alpha Healthcare Acquisition Corporation (AHAC)

10,96
0,00
(0,00%)
Geschlossen 05 November 10:00PM
0,00
0,00
(0,00%)
Nach Börsenschluss: -

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Current Price
10,96
Gebot
10,75
Fragen
10,96
Volumen
-
0,00 Tagesbereich 0,00
0,00 52-Wochen-Bereich 0,00
Marktkapitalisierung
Handelsende
10,96
Handelsbeginn
-
Letzte Trade
Letzter Handelszeitpunkt
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
-
Ausgegebene Aktien
206.578.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-20,44
Gewinn pro Aktie (EPS)
-0,54
Erlöse
-
Nettogewinn
-110,78M

Über Alpha Healthcare Acquisition Corporation

Alpha Healthcare Acquisition Corp is a blank check company. Alpha Healthcare Acquisition Corp is a blank check company.

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-

AHAC Neueste Nachrichten

Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.

Humacyte raises $245M gross proceedsCombined company is expected to begin trading on the Nasdaq Global Select Market® under “HUMA” and “HUMAW” on August 27, 2021Company well-positioned to deliver...

Alpha Healthcare Acquisition Corp. Announces Shareholder Approval of Business Combination with Humacyte

NEW YORK and DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, today announced that its...

Humacyte Announces Addition of Chief Commercial Officer and Integration of Commercial-Scale Manufacturing into Clinical Trial Programs

Appoints proven commercial leader B.J. Scheessele as Chief Commercial OfficerIn-house Durham, N.C. facility is operational and supplying clinical trial material produced in commercial-scale...

Humacyte Announces Publication of In Vivo Data on Biovascular Pancreas Transplantation for the Treatment of Type 1 Diabetes

Data demonstrate biovascular pancreas may have the potential to provide an effective and safe method for pancreatic islet cell transplantation for the treatment of type 1 diabetes Data published...

Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on Humacyte Business Combination

Special shareholder meeting to approve, among other items, the proposed business combination with Humacyte, Inc. to be held August 24, 2021, at 10:00 a.m. EDTShareholders as of the close of...

Humacyte Presents Potential of Functional Lung Engineering at Janelia R3 – Replace, Repair, Regenerate Planning Workshop

DURHAM, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale...

UPDATE -- Humacyte Expands Strategic Global Partnership with Fresenius Medical Care

Partnership expanded to include vascular trauma repair outside of the United States.Fresenius Medical Care is a leading participant in fully committed PIPE financing transaction. DURHAM, N.C...

Humacyte Expands Strategic Global Partnership with Fresenius Medical Care

Partnership expanded to include vascular trauma repair outside of the United States.Fresenius Medical Care will adopt the HAV as a standard of care in patients who will benefit from clinical and...

Humacyte Presents In Vivo Data on Biovascular Pancreas Transplantation for Type 1 Diabetes Treatment

Laboratory and preclinical models demonstrate biovascular pancreas platform technology may provide method to transplant islet cells that produce insulin in Type 1 diabetes patientsData presented...

Humacyte to Provide Investor Update on June 7

DURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
SPPLSIMPPLE Ltd
US$ 1,18
(268,75%)
401,57M
NUWENewellis Inc
US$ 2,80
(105,88%)
99,64M
ADNAdvent Technologies Holdings Inc
US$ 3,34
(75,79%)
64,31M
STAFStaffing 360 Solutions Inc
US$ 2,8301
(66,48%)
52,44M
OMICSingular Genomics Systems Inc
US$ 22,28
(65,53%)
320,13k
TOIIWOncology Institute Inc
US$ 0,0101
(-47,67%)
58,23k
SSPEW Scripps Company
US$ 2,2701
(-35,51%)
4,25M
GCTKGlucoTrack Inc
US$ 1,15
(-33,91%)
82,44k
ILLRTriller Group Inc
US$ 2,86
(-33,18%)
2,32M
FGFFundamental Global Inc
US$ 15,2501
(-31,46%)
209,33k
SPPLSIMPPLE Ltd
US$ 1,18
(268,75%)
401,58M
ELABElevai Labs Inc
US$ 0,0202
(-30,10%)
288,54M
NVDANVIDIA Corporation
US$ 136,05
(0,48%)
187,36M
SQQQProShares UltraPro Short QQQ
US$ 7,52
(1,08%)
167,17M
DJTTrump Media and Technology Group Corporation
US$ 34,34
(12,37%)
120,77M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock